NEW YORK August 14, 2019 – Pretomanid, a novel compound developed by the non-profit organization TB Alliance, was approved by the U.S. Food & Drug Administration (FDA) today for treating some of the most drug-resistant forms of tuberculosis…Original Article
FDA Approves Pretomanid for Highly Drug-Resistant Forms of Tuberculosis
